(Circulation. 2000;102:2803.)
© 2000 American Heart Association, Inc.
Clinical Investigation and Reports |
Simvastatin Improves Disturbed Endothelial Barrier Function
From the Gaubius Laboratory TNO-PG (G.P.v.N.A., M.A.V., P.N.-A., J.J.E., V.W.M.v.H.), Leiden; the Department of Physiology (G.P.v.N.A., V.W.M.v.H.), Institute for Cardiovascular Research, Vrije Universiteit, Amsterdam; and the Department of Medical Oncology (J.L.), University Hospital, Vrije Universiteit, Amsterdam, the Netherlands
Correspondence to Prof Dr V.W.M. van Hinsbergh, Gaubius Laboratory TNO-PG, PO Box 2215, 2301 CE Leiden, Netherlands. E-mail VWM.VANHINSBERGH{at}PG.TNO.NL
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background—Recent clinical trials have established that inhibitors of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase (statins) reduce the risk of acute coronary events. These effects of statins cannot be fully explained by their lipid-lowering potential. Improved endothelial function may contribute to the positive effects of statin treatment.
Methods and Results—In the present study, we report that simvastatin reduces endothelial barrier dysfunction, which is associated with the development of atherosclerosis. Treatment of human umbilical vein endothelial cells for 24 hours with 5 µmol/L simvastatin reduced the thrombin-induced endothelial barrier dysfunction in vitro by 55±3%, as assessed by the passage of peroxidase through human umbilical vein endothelial cell monolayers. Similar effects were found on the thrombin-induced passage of 125I-LDL through human aortic endothelial cell monolayers. This reduction in barrier dysfunction by simvastatin was both dose and time dependent and was accompanied by a reduction in the thrombin-induced formation of stress fibers and focal adhesions and membrane association of RhoA. Simvastatin treatment had no effect on intracellular cAMP levels. In Watanabe heritable hyperlipidemic rabbits, treatment for 1 month with 15 mg/kg simvastatin reduced vascular leakage in both the thoracic and abdominal part of the aorta, as evidenced by the Evans blue dye exclusion test. The decreased permeability was not accompanied by a reduction of oil red O–stainable atherosclerotic lesions.
Conclusions—These data show that simvastatin, in a relatively high concentration, improves disturbed endothelial barrier function both in vitro and in vivo. The data also support the beneficial effects of simvastatin in acute coronary events by mechanisms other than its lipid-lowering effect.
Key Words: cells • statins • endothelium • thrombin
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Recent clinical trials have shown that statins, inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme of cholesterol synthesis in the liver, are effective in the prevention of acute coronary events. Further analysis of these studies suggests that the benefits of statin therapy cannot be fully explained on the basis of reductions in plasma cholesterol levels.1 2 Recent studies have demonstrated that treatment of hypercholesterolemic patients with statins improves endothelial function and vasomotion.3 4 These effects of statins on endothelial function can be fast in onset, inasmuch as an improvement of endothelial function was reported within 1 month of simvastatin therapy in patients with moderate serum cholesterol.5
Experimental atherosclerosis in hypercholesterolemia models is associated with changes in endothelial integrity (see review6 ). Additionally, during the development of atherosclerosis, the permeability of the vessel wall for LDL increases (see review7 ). Because gross endothelial loss probably only occurs very late in the development of atherosclerosis, dysfunction of the intact endothelial layer provides a more likely explanation for the increase in permeability.
The endothelial actin cytoskeleton is important in maintaining the structural integrity of the endothelium.8 The junction-associated actin filament system forms a dense peripheral band of F-actin and is the most prominent assembly in the majority of endothelial cells.8 Activation of the endothelium by inflammatory mediators results in a contraction process at the margins of the cell. Small gaps between neighboring cells are formed, increasing the permeability of the endothelium. In vitro, these changes in permeability are accompanied by the formation of long F-actin filaments or stress fibers.9 In vivo, endothelial stress fibers are found in areas of altered flow. The function of these stress fibers is not precisely known at the moment, but they could have contractile properties.10
In the present study, we investigated whether simvastatin could improve disturbed endothelial barrier function, in both in vitro and in vivo models of endothelial perturbation.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Materials
Tissue culture plastics and Transwells (diameter 0.65 cm, pore size 3 µm) were obtained from Corning Costar; cell culture reagents were as described previously.9 Bovine thrombin was from Leo Pharmaceutical Products. Horseradish peroxidase (HRP), Evans blue, oil red O, and anti-vinculin immunoglobulin were obtained from Sigma Chemical Co. Rhodamine-phalloidin was from Molecular Probes. Rabbit anti-mouse IgG-FITC was from Dakopatts. Simvastatin-lactone used in the in vitro studies was from Merck, Sharp & Dohme, and simvastatin-lactone used in the in vivo studies was from Sankyo. 125I was purchased from Amersham. Pyrogen-free human serum albumin (HSA) was from the Central Laboratory of the Blood Transfusion Service, Amsterdam, the Netherlands.
Cell Culture and Evaluation of Barrier Function
In Vitro
Human endothelial cells were isolated and cultured as
described
previously.11 Cells
were seeded at high density and grown on fibronectin-coated
polycarbonate filters of the Transwell system for 4 to 6 days until
highly confluent monolayers were
obtained.9 12
Culture medium was renewed every other day (medium 199, 10% human
serum, 10% newborn calf serum, 150 µg/mL crude endothelial cell
growth factor, 5 U/mL heparin, 100 IU/mL penicillin, and 100 µg/mL
streptomycin). Subsequently, cells were treated with simvastatin (0.1
to 5.0 µmol/L) for the indicated time points (usually 24 hours) in
culture medium. After treatment with simvastatin, cells were washed
with medium 199/1% HSA to remove serum, incubated for 1 hour in medium
199/1% HSA, and subsequently stimulated with thrombin. Barrier
function was evaluated by the transfer of HRP or
125I-LDL across human umbilical vein
endothelial cell (HUVEC, after 1 passage) or human aortic endothelial
cell (EC, after 4 passages) monolayers. In short, HRP or
125I-LDL was added to the upper compartment
of the Transwells, samples were taken from the lower compartment at
various time intervals, and the volume was adjusted by medium 199/1%
HSA. HRP concentration was determined spectrophotometrically in each
sample with peroxide and tetramethyl
benzidine.125I-LDL concentration was
determined in a 
-counter after trichloroacetic acid precipitation to
correct for degradation of the LDL particle.
Preparation and Iodination of LDLs
LDL was isolated from fresh serum prepared from the
blood of healthy volunteers by gradient
ultracentrifugation13
and labeled with 125I as previously
described.12
Extraction and Assay of Intracellular cAMP
Levels
Intracellular cAMP levels were determined by
radioimmunoassay from Amersham as described
previously.9 11
Immunocytochemistry
The presence of vinculin and F-actin was visualized
by indirect immunofluorescence with mouse anti-vinculin antibody and by
direct staining with rhodamine-phalloidin with use of a confocal laser
scan microscope (type TCS 4D, Leica Heidelberg). Overlaying of pictures
was accomplished with Photo-Paint software (version 6.00, 1995, Corel
Co).
Detection of Cytosolic and Membrane-Bound
RhoA
Confluent endothelial monolayers were preincubated
for 24 hours with 5 µmol/L simvastatin in normal culture medium. One
hour before lysis, the cell culture medium was replaced by medium
199/1% HSA. After they were washed with PBS, the cells were lysed in
300 µL/10 cm2 ice-cold hypotonic lysis
buffer (5 mmol/L Tris-HCl, pH 7.0, 5 mmol/L NaCl, 1 mmol/L
CaCl2, 2 mmol/L EGTA, 1 mmol/L
MgCl2, 2 mmol/L dithiothreitol, and freshly
added protease inhibitors [Complete, Boehringer]) and incubated for
30 minutes on ice. Cells were scraped and sucked 5 times through a
25-gauge needle. Membrane and cytosolic fractions were separated by
centrifugation at 100 000g for 1 hour. The pellet was
dissolved in an equal volume of lysis buffer+1% Triton X-100. Proteins
were separated on SDS-PAGE and transferred to polyvinylidine
difluoride, and immunoblotting was performed with the use of an
antibody to RhoA (Santa Cruz Biotechnology Inc). Immunodetection was
accomplished with the use of a goat anti-rabbit secondary antibody and
an enhanced chemoluminescence kit (ECL kit, Amersham
Corp).
Animals
Sixteen-month-old Watanabe heritable hyperlipidemic
rabbits were obtained from the Oriental Yeast Co, Tokyo, Japan. They
were housed individually and fed standard rabbit chow ad libitum, with
water supplied ad libitum. For 4 weeks before euthanasia, the animals
received simvastatin-lactone (15.0 mg/kg body wt) daily, in addition to
the standard rabbit chow.
Cholesterol Measurement
Total serum cholesterol was determined by using a
commercially available enzymatic kit (Roche
Diagnostics).
Evaluation of Vascular Leakage and
Atherosclerosis
Animals were sedated with Hypnorm (0.4 mL/kg
IM; Janssen Pharmaceutical), mildly anticoagulated with heparin (500
U/rabbit IV), and euthanized with pentobarbital sodium (2.5 mL/kg IV).
Aortas were rapidly removed and cleaned from the adjacent tissue. They
were perfused with medium 199 buffered with Hanks’ salts, 100 IU/mL
penicillin, 100 µg/mL streptomycin, and 1% HSA to remove blood
cells; subsequently, with Evans blue in medium 199 (0.3% [wt/vol])
for 5 minutes; and finally, with medium 199 to remove unbound Evans
blue. They were then fixed with 3.7% buffered formaldehyde. Aortas
were opened longitudinally and photographed en face with use of a
digital Nikon Coolpix 900 camera. Evans blue staining was quantified
4-fold with Tina image analysis software (Raytest), and optical density
was expressed in arbitrary units per square millimeter.
Subsequently, the extent of atherosclerosis was assessed by staining the Evans blue–treated aortic segments with oil red O and evaluated.
Statistical Analysis
Data are reported as mean±SEM. Comparisons between
>2 groups were made by 1-way ANOVA, followed by a Bonferroni-adjusted
2 test. Comparisons of time curves of 2
groups were made by repeated-measures MANOVA, and individual group
comparisons were performed by a Student t test for
post hoc comparisons of the means. Differences were considered
significant at the P<0.05 level.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Effects of Simvastatin on In Vitro Endothelial Barrier Function
Confluent HUVEC and human aortic EC monolayers were incubated for 24 hours in medium 199 containing 5 µmol/L simvastatin in the presence of serum to evaluate the effect on cell morphology (Figure 1
). Simvastatin-treated ECs remained tightly
confluent, but cells were slightly elongated (which was most easily
visible in aortic monolayers) with a condensed cytoplasm around the
nucleus.
|
To test whether simvastatin influences endothelial barrier
function, HUVECs were grown to confluence on porous filters, and the
passage of a marker protein (HRP, 42 to 44 kDa) was measured.
Pretreatment with 5 µmol/L simvastatin for 24 hours slightly
increased HRP passage. However, the thrombin-induced HRP passage was
significantly decreased
(Figure 2A). This simvastatin pretreatment inhibited
thrombin-induced HRP passage by 55±3% during a 1-hour incubation
period (mean±SEM, 5 different cultures in triplicate). The reduction
was concentration dependent
(Figure 2B) and was maximal at 5 µmol/L simvastatin. Higher
concentrations were not used because they affected basal EC barrier
function. Lower concentrations of simvastatin required longer
incubation periods. Preincubation with 0.5 µmol/L simvastatin for 96
hours reduced the thrombin-enhanced HRP passage by 35±5% (mean±SEM;
6 filter cultures of 2 different donors,
Figure 2C). Coincubation with mevalonate fully abolished the
effect of simvastatin on cell morphology (not shown) and
thrombin-induced HRP passage
(Figure 2B), indicating that simvastatin reduced the
thrombin-induced HRP passage by inhibition of HMG-CoA reductase.
Simvastatin inhibited the thrombin-induced HRP passage in a
time-dependent manner
(Figure 2D). This inhibition was maximal after 8 hours of
simvastatin pretreatment and continued for at least 24 hours. Because
atherosclerosis is associated with an enhanced passage of LDL across
the aortic endothelium and an increase in the accumulation of LDL in
the aortic wall,7 we
preincubated human aortic EC monolayers with simvastatin and measured
its effect on (thrombin-induced) 125I-LDL
passage. Simvastatin slightly increased basal aortic endothelial
permeability but attenuated thrombin-enhanced LDL passage and was
maximally effective at 2 µmol/L
(Figure 2E).
|
, 
) or without
Simva (
, •). HRP passage was measured under basal conditions (
Effect of Simvastatin on Permeability Does Not
Involve cAMP or Endothelial NO Synthase
Elevation of intracellular cAMP levels is known to
improve endothelial barrier
function.14 When
HUVECs were preincubated with 5 µmol/L simvastatin for 24 hours, cAMP
concentrations remained unaltered both under basal conditions (2.6±0.2
and 1.9±0.4 pmol per 3.5x105 cells in
control and simvastatin-pretreated cells, respectively) and after a
2-minute stimulation of the cells with 1 U/mL thrombin (2.5±0.8 and
2.1±0.4 pmol per 3.5x105 cells,
respectively) or after a 30-minute stimulation (2.6±0.1 and 2.1±0.2
pmol per 3.5x105 cells, respectively) (3
experiments). As a positive control, cells were pretreated for 15
minutes with 10 µmol/L forskolin, which raised intracellular cAMP
concentration to 9.0±0.4 pmol per 3.5x105
cells. This excludes elevation of cAMP as the mechanism of
action.
Statins can increase the cellular amount of endothelial NO synthase (eNOS).15 16 NO counteracts the thrombin-induced permeability in our model.17 Although prolonged incubation (>24 hours) of HUVECs and aortic ECs with simvastatin indeed increased the level of eNOS protein, simvastatin had no effect on eNOS protein expression within the 24-hour incubation period in our experimental conditions (Western blotting, data not shown).
Effect of Simvastatin on Localization of
Vinculin and F-Actin of Basal and Thrombin- Stimulated
Monolayers
The actin cytoskeleton of ECs is important in
maintaining the structural integrity of the
endothelium.8 HUVEC
monolayers were stained for vinculin, a marker for focal adhesion
formation, and for F-actin. Control cells showed hardly any vinculin
staining and were characterized by cortical F-actin microfilaments
(Figure 3A to 3C), indicating the resting state of the
monolayers. Thrombin induced a dramatic increase in the formation of
focal adhesions and stress fibers
(Figure 3G to 3I). Many small gaps between the cells were
observed. Pretreatment with simvastatin decreased basal F-actin
filaments, and only a thin peripheral rim of F-actin remained
(Figure 3D to 3F). Formation of focal adhesions by thrombin
was reduced by simvastatin pretreatment, as was the formation of stress
fibers and of gaps
(Figure 3J to 3L). Thus, simvastatin to a large extent
prevented the thrombin-induced changes of the EC
cytoskeleton.
|
Simvastatin Affects Membrane Translocation
of RhoA
It has been shown previously that the small GTPase RhoA
is involved in the thrombin-induced endothelial hyperpermeability and
accompanying cytoskeletal
rearrangements.9 18 19
Isoprenylation of small GTPases, which is essential for their
translocation to the plasma membrane, is inhibited by
statins.15 20 21
Under resting conditions, a small fraction of the cellular
RhoA content was present in the plasma membrane
(Figure 4). Treatment with simvastatin (5 µmol/L for 24
hours) reduced the membrane localization of RhoA. Stimulation with
thrombin for 30 minutes induced the translocation of RhoA to the
membrane fraction, which was completely prevented by preincubation with
simvastatin. Mevalonate reversed the effects of simvastatin (data not
shown).
|
Simvastatin Treatment Reduces Vascular Leakage
In Vivo
To test whether simvastatin could improve endothelial
barrier function in vivo, Watanabe rabbits were treated with 15 mg/kg
body wt simvastatin over 4 weeks. Simvastatin induced a slight
nonsignificant reduction in plasma cholesterol (from 10.2±2.7 mmol/L
before to 8.5±2.1 mmol/L after simvastatin treatment,
P=0.30; n=3), but cholesterol levels remained elevated
after this relatively short treatment period. After the animals were
euthanized, endothelial barrier function of the thoracic and abdominal
aorta was assessed ex vivo by determining the penetration of the Evans
blue–albumin complex in the vessel wall. In the thoracic aortas of
control animals, an intense blue staining was observed
(Figure 5A). Treatment with simvastatin reduced Evans blue
staining
(Figures 5A and 6). Similar results were obtained in the
abdominal aorta of the same rabbits
(Figure 6).
|
|
To exclude the possibility that the decrease in endothelial
permeability by simvastatin treatment was due to a reduction in the
extent of atherosclerotic plaques, the same aortic segments were
subsequently stained with oil red O. Aortas either from control or
simvastatin-treated animals were severely atherosclerotic, with no
visible changes in lipid accumulation after simvastatin treatment for 4
weeks
(Figure 5B
). As a control, umbilical veins, which showed no
oil red O staining, were used (data not shown). It is of interest to
note that in the control animals, a strong blue staining was observed
in the areas of low lipid accumulation
(Figure 5A, white arrow). This extravasation is not likely to
be caused by endothelial damage, because in aortic areas of
simvastatin-treated animals with a comparable low degree of lipid
accumulation
(Figure 5B, yellow arrow), a relatively small amount of Evans
blue–albumin complex was observed
(Figure 5A, yellow arrow). This exclusion of Evans blue dye
indicates the presence of an intact endothelial barrier. It is likely
that the accumulated lipids interfered with maximal accumulation of
Evans blue.
Thus, simvastatin had already improved vascular barrier function in Watanabe rabbits at a time point at which no obvious changes in the extent of atherosclerotic plaques were observed.
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The major finding of the present study is that simvastatin treatment reduced endothelial barrier dysfunction both in an established in vitro model of endothelial permeability consisting of human ECs grown on porous filters and in ex vivo aortic segments of Watanabe rabbits, which have an increased endothelial permeability.
Accumulation of LDL in the arterial wall is one of the hallmarks of the development of atherosclerosis. The focal nature of plaque formation is remarkably similar to the focal occurrence of vascular leakage sites.7 In laboratory animals, the regional variation in the arterial wall permeability predicts the pattern of experimental atherosclerosis. It is not known at the moment whether this association reflects a causal relationship. Our finding, ie, that simvastatin treatment, which decreases the progression of atherosclerosis, reduces enhanced permeability, supports the idea that an increased permeability to LDL increases the risk of atherosclerosis and that a reduction in endothelial permeability, in addition to a lowering in plasma LDL concentration, may assist in the prevention of the progression of atherosclerosis.
We have previously shown that NO improves the endothelial barrier in vitro and acts as a negative feedback regulator of the thrombin-induced barrier dysfunction.17 Statins can increase eNOS expression on the posttranscriptional level in ECs exposed to oxidizing conditions.15 16 However, during the relatively short period of our in vitro experiments, the cellular eNOS antigen concentration did not change. This excluded the possibility that simvastatin improves barrier function by increasing NO production. Nor did simvastatin have any effect on intracellular cAMP concentration, which also improves endothelial barrier function.14
Simvastatin reduced F-actin staining in control HUVEC monolayers, in accordance with the decrease in F-actin content by lovastatin treatment in NIH 3T3 cells.22 Furthermore, simvastatin largely reduced the formation of stress fibers induced by thrombin. This finding is of interest because prominent stress fibers are found in endothelial cells in vivo in areas prone to the development of atherosclerosis.6
Several authors have shown that statins may affect the F-actin cytoskeleton through inactivation of Rho proteins.20 22 Lovastatin prevented the lysophosphatidic acid–induced translocation of RhoA and cell contraction in neuronal cells by inhibition of isoprenylation of RhoA.20 An effect of statins on Rho proteins in vascular smooth muscle and ECs has also recently been indicated.15 21 We and others have previously shown that RhoA is involved in the thrombin-induced endothelial barrier dysfunction in vitro, which involves Rho kinase–dependent inhibition of myosin light chain phosphorylation.9 18 19 In accordance, we now demonstrate that simvastatin prevents both the basal and the thrombin-induced translocation of RhoA to the plasma membrane. In these experiments, compared with other studies,15 a low fraction of RhoA was present in the plasma membrane under resting conditions. This explains that no accompanying increase in cytosolic RhoA was observed after treatment with simvastatin. To our knowledge, no in vivo data are yet available on the role of activation of RhoA in vascular leakage.
Improvement of endothelial integrity by simvastatin in vivo was probably not due to a reduction of atherosclerotic lesions. A short regimen of 4 weeks of simvastatin treatment was chosen, which had only a moderate effect on plasma cholesterol levels (17% reduction). No visible plaque regression was detectable in the rabbit aortas after oil red O staining. We cannot exclude the possibility that circulating LDL in the control animals contains an endothelium-activating fraction, which is reduced in parallel with the drop in plasma cholesterol. However, we feel more likely that the prevention of RhoA activation explains the improved barrier function.
Highly confluent cells were required to demonstrate the positive effect of simvastatin on disturbed barrier function in vitro (authors’ unpublished data, 2000). One explanation for this finding may be that because statins are known to inhibit cell proliferation, nonconfluent monolayers were not able to reach confluence in the presence of simvastatin.23 Furthermore, in vascular smooth muscle cells, statins are known to induce apoptosis at high concentration.21 Taken together, these findings suggest that care has to be taken to use statins when endothelial cells are in a proliferative state, eg, in wound healing.
Treatment of patients suffering from prolonged edema has been less successful with current therapies until now. Although ß-adrenergic agents have been shown to be effective in acutely induced vascular leakage, when they are administered in the presence of capillary leakage syndrome, desensitization to ß-adrenergic agents occurs after 1 day.24 Future studies are necessary to investigate whether statin treatment could reduce vascular leakage under these conditions. The recent finding that simvastatin reduces leukocyte-endothelium interactions indicates that statins also have an effect on the microvascular endothelium.25 Our finding may also bear importance for stented vascular areas, inasmuch as previous work has demonstrated prolonged leakage in these areas.26
In conclusion, we found that simvastatin, in a relatively high concentration, reduces endothelial permeability and that this decrease in permeability was accompanied by a decrease in cell F-actin content. These findings may have implications for the treatment of patients with a high risk of developing atherosclerosis and of those with implanted stents and possibly of patients with capillary leakage syndrome.
|
Acknowledgments |
|---|
This study was financially supported by the Netherlands Heart Foundation (grant 94.048) and the Vrije Universiteit Stimuleringsfonds. We would like to thank B. van Dam for performing eNOS Western blotting. The technical assistance of M. Bekkers, H. Dekker, and R. van Leeuwen is gratefully acknowledged.
Received May 15, 2000; revision received July 14, 2000; accepted July 17, 2000.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet. 1996;348:1079–1082.[Medline] [Order article via Infotrieve]
2. Shepherd J. A tale of two trials: the West of Scotland Coronary Prevention Study and the Texas Coronary Atherosclerosis Prevention Study. Atherosclerosis. 1998;139:223–229.[Medline] [Order article via Infotrieve]
3.
Egashira
K, Hirooka Y, Kai H, et al. Reduction in serum cholesterol with
pravastatin improves endothelium-dependent coronary vasomotion in
patients with hypercholesterolemia. Circulation. 1994;89:2519–2524.
4.
Treasure
CB, Klein JL, Weintraub WS, et al. Beneficial effects of
cholesterol-lowering therapy on the coronary endothelium in patients
with coronary artery disease. N Engl J Med. 1995;332:481–487.
5.
O’Driscoll
G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase
inhibitor, improves endothelial function within 1 month.
Circulation. 1997;95:1126–1131.
6.
Colangelo
S, Langille BL, Steiner G, et al. Alterations in endothelial F-actin
microfilaments in rabbit aorta in hypercholesterolemia.
Arterioscler Thromb Vasc Biol. 1998;18:52–56.
7. Nielsen LB. Transfer of low density lipoprotein into the arterial wall and the risk of atherosclerosis. Arteriosclerosis. 1996;123:1–15.
8. Drenckhahn D, Ness W. The endothelial contractile cytoskeleton. In: Born GVR, Schwartz CJ, eds. Vascular Endothelium: Physiology, Pathology, and Therapeutic Opportunities. Stuttgart, Germany/New York, NY: Schattauer; 1997:1–25.
9.
Van
Nieuw Amerongen GP, Draijer R, Vermeer MA, et al. Transient and
prolonged increase in endothelial permeability induced by histamine and
thrombin: role of protein kinases, calcium, and RhoA. Circ
Res. 1998;83:1115–1123.
10. Ridley AJ. Stress fibres take shape. Nat Cell Biol. 1999;1:64–66.
11.
Draijer
R, Vaandrager AB, Nolte C, et al. Expression of cGMP-dependent protein
kinase I and phosphorylation of its substrate, vasodilator-stimulated
phosphoprotein, in human endothelial cells of different origin.
Circ Res. 1995;77:897–905.
12.
Langeler
EG, Snelting Havinga I, van Hinsbergh VW. Passage of low density
lipoproteins through monolayers of human arterial endothelial cells:
effects of vasoactive substances in an in vitro model.
Arteriosclerosis. 1989;9:550–559.
13. Redgrave TG, Roberts DCK, West CE. Separation of plasma lipoproteins by density-gradient ultracentrifugation. Anal Biochem. 1975;65:42–49.[Medline] [Order article via Infotrieve]
14.
Van
Hinsbergh VWM. Endothelial permeability for macromolecules: mechanistic
aspects of pathophysiological modulation. Arterioscler Thromb
Vasc Biol. 1997;17:1018–1023.
15.
Laufs
U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide
synthase mRNA stability by Rho GTPase. J Biol
Chem. 1998;273:24266–24271.
16.
Laufs
U, La Fata V, Plutzky J, et al. Upregulation of endothelial nitric
oxide synthase by HMG CoA reductase inhibitors.
Circulation. 1998;97:1129–1135.
17.
Draijer
R, Atsma DE, van der Laarse A, et al. cGMP and nitric oxide modulate
thrombin-induced endothelial permeability: regulation via different
pathways in human aortic and umbilical vein endothelial cells.
Circ Res. 1995;76:199–208.
18.
Essler
M, Amano M, Kruse H-J, et al. Thrombin inactivates myosin light chain
phosphatase via Rho and its target Rho kinase in human endothelial
cells. J Biol Chem. 1998;273:21867–21874.
19.
Van
Nieuw Amerongen GP, Van Delft S, Vermeer MA, et al. Activation of RhoA
by thrombin in endothelial hyperpermeability: role of Rho kinase and
protein tyrosine kinases. Circ Res. 2000;87:335–340.
20. Kranenburg O, Poland M, Gebbink M, et al. Dissociation of LPA-induced cytoskeletal contraction from stress fiber formation by differential localization of RhoA. J Cell Sci. 1997;110(pt 19):2417–2427.
21.
Guijarro
C, Blanco-Colio LM, Ortego M, et al. 3-Hydroxy-3-methylglutaryl
coenzyme A reductase and isoprenylation inhibitors induce apoptosis of
vascular smooth muscle cells in culture. Circ Res. 1998;83:490–500.
22.
Koch G,
Benz C, Schmidt G, et al. Role of Rho protein in lovastatin-induced
breakdown of actin cytoskeleton. J Pharmacol Exp
Ther. 1997;283:901–909.
23. Negre-Aminou P, van Vliet AK, van Erck M, et al. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors: comparison with other human cell types. Biochim Biophys Acta. 1997;1345:259–268.[Medline] [Order article via Infotrieve]
24. Droder RM, Kyle RA, Greipp PR. Control of systemic capillary leak syndrome with aminophylline and terbutaline. Am J Med. 1992;92:523–526.[Medline] [Order article via Infotrieve]
25.
Pruefer
D, Scalia R, Lefer AM. Simvastatin inhibits leukocyte-endothelial cell
interactions and protects against inflammatory processes in
normocholesterolemic rats. Arterioscler Thromb Vasc
Biol. 1999;19:2894–2900.
26.
Van
Beusekom HMM, Whelan DM, Hofma SH, et al. Long-term endothelial
dysfunction is more pronounced after stenting than after balloon
angioplasty in porcine coronary arteries. J Am Coll
Cardiol. 1998;32:1109–1117.
This article has been cited by other articles:
 |
|
 |
|
  C. Rodriguez, J. F. Alcudia, J. Martinez-Gonzalez, A. Guadall, B. Raposo, S. Sanchez-Gomez, and L. Badimon Statins normalize vascular lysyl oxidase down-regulation induced by proatherogenic risk factors Cardiovasc Res, August 1, 2009; 83(3): 595 - 603. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Mira, B. Leon, D. F. Barber, S. Jimenez-Baranda, I. Goya, L. Almonacid, G. Marquez, A. Zaballos, C. Martinez-A., J. V. Stein, et al. Statins Induce Regulatory T Cell Recruitment via a CCL1 Dependent Pathway J. Immunol., September 1, 2008; 181(5): 3524 - 3534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. P. van de Visse, M. van der Heijden, J. Verheij, G. P. van Nieuw Amerongen, V. W. M. van Hinsbergh, A. R. J. Girbes, and A. B. J. Groeneveld Effect of prior statin therapy on capillary permeability in the lungs after cardiac or vascular surgery. Eur. Respir. J., May 1, 2006; 27(5): 1026 - 1032. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Erzen, P. Gradisek, P. Poredos, and M. Sabovic Treatment of Essential Arterial Hypertension with Enalapril Does Not Result in Normalization of Endothelial Dysfunction of the Conduit Arteries Angiology, March 1, 2006; 57(2): 187 - 192. [Abstract] [PDF]
|
|
|
|
 |
|
 K. Iwakura, H. Ito, S. Kawano, A. Okamura, T. Kurotobi, M. Date, K. Inoue, and K. Fujii Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction Eur. Heart J., March 1, 2006; 27(5): 534 - 539. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Haas, M. H. Horani, S. A. Parseghian, and A. D. Mooradian Statins Prevent Dextrose-Induced Endothelial Barrier Dysfunction, Possibly Through Inhibition of Superoxide Formation Diabetes, February 1, 2006; 55(2): 474 - 479. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Mooradian, M. J. Haas, O. Batejko, M. Hovsepyan, and S. S. Feman Statins Ameliorate Endothelial Barrier Permeability Changes in the Cerebral Tissue of Streptozotocin-Induced Diabetic Rats Diabetes, October 1, 2005; 54(10): 2977 - 2982. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Jacobson, J. W. Barnard, D. N. Grigoryev, S.-F. Ma, R. M. Tuder, and J. G. N. Garcia Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury Am J Physiol Lung Cell Mol Physiol, June 1, 2005; 288(6): L1026 - L1032. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Liu, H. Jiang, and R. W. Grange Genistein Activates the 3',5'-Cyclic Adenosine Monophosphate Signaling Pathway in Vascular Endothelial Cells and Protects Endothelial Barrier Function Endocrinology, March 1, 2005; 146(3): 1312 - 1320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. O. Harrington, J. Newton, N. Morin, and S. Rounds Barrier dysfunction and RhoA activation are blunted by homocysteine and adenosine in pulmonary endothelium Am J Physiol Lung Cell Mol Physiol, December 1, 2004; 287(6): L1091 - L1097. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Coupel, F. Leboeuf, G. Boulday, J.-P. Soulillou, and B. Charreau RhoA Activation Mediates Phosphatidylinositol 3-Kinase-Dependent Proliferation of Human Vascular Endothelial Cells: An Alloimmune Mechanism of Chronic Allograft Nephropathy J. Am. Soc. Nephrol., September 1, 2004; 15(9): 2429 - 2439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Jacobson, S. M. Dudek, K. G. Birukov, S. Q. Ye, D. N. Grigoryev, R. E. Girgis, and J. G. N. Garcia Cytoskeletal Activation and Altered Gene Expression in Endothelial Barrier Regulation by Simvastatin Am. J. Respir. Cell Mol. Biol., May 1, 2004; 30(5): 662 - 670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. P. van Nieuw Amerongen, K. Natarajan, G. Yin, R. J. Hoefen, M. Osawa, J. Haendeler, A.J. Ridley, K. Fujiwara, V. W.M. van Hinsbergh, and B. C. Berk GIT1 Mediates Thrombin Signaling in Endothelial Cells: Role in Turnover of RhoA-Type Focal Adhesions Circ. Res., April 30, 2004; 94(8): 1041 - 1049. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. P. van Nieuw Amerongen, P. Koolwijk, A. Versteilen, and V. W.M. van Hinsbergh Involvement of RhoA/Rho Kinase Signaling in VEGF-Induced Endothelial Cell Migration and Angiogenesis In Vitro Arterioscler Thromb Vasc Biol, February 1, 2003; 23(2): 211 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Rashid, K. D. Uffelman, P. H. R. Barrett, and G. F. Lewis Effect of Atorvastatin on High-Density Lipoprotein Apolipoprotein A-I Production and Clearance in the New Zealand White Rabbit Circulation, December 3, 2002; 106(23): 2955 - 2960. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. C. Kraynack, D. A. Corey, H. L. Elmer, and T. J. Kelley Mechanisms of NOS2 regulation by Rho GTPase signaling in airway epithelial cells Am J Physiol Lung Cell Mol Physiol, September 1, 2002; 283(3): L604 - L611. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. P. van Nieuw Amerongen and V. W.M. van Hinsbergh Cytoskeletal Effects of Rho-Like Small Guanine Nucleotide-Binding Proteins in the Vascular System Arterioscler Thromb Vasc Biol, March 1, 2001; 21(3): 300 - 311. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||